+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in second-line treatment of castration-resistant prostate cancer

Recent advances in second-line treatment of castration-resistant prostate cancer

Current Opinion in Supportive and Palliative Care 5(3): 199-205

Patients with metastatic castration-resistant prostate cancer (CRPC) no longer responsive to docetaxel have a poor prognosis, worsened quality-of-life, and traditionally few options for treatment. This review addresses promising and practice-changing developments for the treatment of CRPC in the second-line setting. Recent data for cabazitaxel, a novel taxane chemotherapy, and abiraterone acetate, a novel inhibitor of androgen synthesis, demonstrate significant improvements in the survival of patients with docetaxel-refractory CRPC. We review the mechanisms of action of these agents and data from phase III clinical trials, contextualizing their place in therapy. We also update other areas of investigation, including oral platinum analogues, vascular-endothelial growth factor receptor targeted therapy, inhibitors of chaperone proteins, and androgen receptor antagonists. Upon disease progression after first-line docetaxel chemotherapy, cabazitaxel and abiraterone improve survival of patients with CRPC and are important novel treatment options. Potential toxicity from cabazitaxel necessitates careful patient selection and supportive care. Both abiraterone and cabazitaxel are also being evaluated in the first-line setting, and therefore the optimal sequencing of therapies remains uncertain. Many other novel agents continue to be evaluated and promising classes of agents include antisense oligonucleotides against clusterin (custirsen) and androgen receptor antagonists (MDV3100).

(PDF emailed within 0-6 h: $19.90)

Accession: 055398592

Download citation: RISBibTeXText

PMID: 21734586

DOI: 10.1097/SPC.0b013e32834903aa

Related references

Recent advances in treatment of patients with castration-resistant prostate cancer after docetaxel failure. Zhejiang Da Xue Xue Bao. Yi Xue Ban 43(1): 115-118, 2014

Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer. Pharmaceutical Patent Analyst 4(5): 387-402, 2016

Recent Advances In The Treatment Of Metastatic Castration Resistant Prostate Cancer: Impact On Health Related Quality Of Life. Value in Health 16(3): A146-A147, 2013

Recent advances in the management of castration-resistant prostate cancer. Clinical Advances in Hematology and Oncology 11(3): 181-183, 2013

Management of metastatic castration-resistant prostate cancer: recent advances. Drugs 72(8): 1011-1028, 2012

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. Frontiers in Oncology 8: 397, 2018

Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer. Oncotargets and Therapy 11: 3167-3178, 2018

Recent advances in the therapy of castration-resistant prostate cancer: the price of progress. Maturitas 70(2): 194-196, 2012

Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. Current Treatment Options in Oncology 20(2): 14, 2019

Guideline Adherence In Docetaxel Treatment Of Castration Resistant Prostate Cancer (CRPC) Patients In A Real-World Population: The Castration Resistant Prostate Cancer Registry (CAPRI) In The Netherlands. Value in Health 20(9): A471-A472, 2017

Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel. Urologic Oncology 30(6): 762-771, 2013

Advances in the treatment of castration-resistant prostate cancer: emphasis in new hormonal therapies. Revista Medica de Chile 143(2): 223-236, 2015

Study and therapy of metastatic castration-resistant prostate cancer: A randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAC/PCa versus placebo in men with metastatic castration resistant prostate cancer eligible for first line chemotherapy (VIABLE) - AUO study AP 78/13. Der Urologe. Ausg. a 54(4): 555-557, 2016

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Design, Development and Therapy 5: 117-124, 2011

Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer. Drugs 72(11): 1559-1577, 2012